Royal Philips has entered a strategic collaboration with health monitoring and clinical intelligence company BioIntelliSense to enhance remote monitoring for at-risk patients at home.

As part of the collaboration, the company will integrate BioIntelliSense’s BioSticker medical device into its remote patient monitoring (RPM).

The BioSticker is a single-use, FDA-cleared 510k class II wearable medical device that allows at-home constant passive monitoring.

It provides clinicians with minute level data, including vital signs, physiological biometrics and symptomatic events such as skin temperature and resting heart rate.

With the addition of multi-parameter sensors, Philips’ solutions will enable clinicians to monitor patients with chronic conditions in their homes through a discreet wearable patch for up to 30 days.

The solution will also help clinicians in the US gain critical insights into a patient’s condition so that they can facilitate early intervention, as well as reduce the need for clinicians and patients to interact in person, especially during the Covid-19 pandemic.

Royal Philips Connected Care chief business leader Roy Jakobs said: “With more patients interacting with their doctors from home and more hospitals developing strategies to virtually engage with their patients, remote patient monitoring is now, more than ever, an essential tool.”

BioIntelliSense founder and CEO James Maultsaid: “Multi-parameter sensors are the natural next phase for remote monitoring, especially at a time when more patients are engaging with their physicians from home.

“Philips is a demonstrated leader in remote patient monitoring, and we look forward to BioIntelliSense’s technology playing an integral role in simplifying and enhancing outcomes for patients and their doctors.”